Pharmaceutical company, Genetech, recently announced the FDA's approval of their new port delivery system, Susvimo, for the treamtment of wet age-related macular degeneration.
Susvimo is a refillable eye implant that requires a single outpatient
procedure to place the device under the upper eyelid. The device is the size of a grain of rice and is refilled every six months with Regeneron's anti-VEGF treatment, Lucentis.
This new therapy allows patients an alternative to the current intravitreal injections which are administered every 4 to 8 weeks. The frequency and cost of the injections often contributes to non-compliance among patients.
In clinical trials, Susvimo was well-tolerated and more than 98% of patients were able to go up to six months between refills.
